Senators Slam GSK, FDA On Avandia Safety

Law360, New York (February 22, 2010, 2:53 PM EST) -- Senators have blasted GlaxoSmithKline PLC for not alerting patients to potential cardiac risks associated with diabetes drug Avandia, and questioned what the FDA has done to ensure the safety of patients involved in an ongoing trial.

In a Senate Finance Committee report and a letter released on Saturday — and immediately disputed by GSK — senators accused GSK of trying to squash reviews that suggested the drug might not be safe.

They also pointed the finger at the FDA, which they suggested was unable to ensure...
To view the full article, register now.